English

Interim Report Q2, 2020

Report this content

Second quarter 2020

All figures for 2020 and 2019 refer to the Group.Other operating income amounted to kSEK 872 (663) 
 

  • Result after taxes amounted to kSEK -4,810 (-4,149)  
  • Basic and diluted earnings per share: SEK -0.05 (-0.05)
  • The cash flow from operating activities was kSEK -5,775 (-3,547)

First half of 2020

  • Other operating income amounted to kSEK 2,057 (1,313).
  • Result after taxes amounted to kSEK -8,594 (-6,925)  
  • Basic and diluted earnings per share: SEK -0.10 (-0.08)
  • The cash flow from operating activities was kSEK -5,342 (-3,576)
  • Cash and cash equivalents amounted to kSEK 42,052 (32,669) on the balance sheet date
  • Solidity: 83 (79)%

Significant events during the second quarter

  • Patent application enters PCT phase, Spectracure ensures development and work. SpectraCure’s work and development proceed with several parallel projects. A patent application which covers a new technology that improves upon the Company’s IDOSE technology has progressed to the so-called PCT phase, which is a way of coordinating patent applications in all the countries of the world. The patent application covers a new technology which increases the accuracy of the Company’s IDOSE technology further.
     
  • The Board of Directors resolved to carry out a new issue of Units, amounting to no more than MSEK 140.
     
  • New developments in project funded by Knut and Alice Wallenberg Foundation. SpectraCure is an industrial participant in a major research programme in quantum technology, WACQT –  Wallenberg Centre for Quantum Technology, which is financed mainly by the Knut and Alice Wallenberg Foundation.
     
  • Patent application submitted to protect new technology. SpectraCure has submitted a new patent application to the European Patent Office.  The patent application regards the technical solution used in the new generation of SpectraCure's treatment system. The technology makes it possible to use the same optical fiber for both treatment and dose monitoring; together with the IDOSE® software, this is what makes the SpectraCure method unique.
     
  • Wider range of prospective patients in the UK, Canada and the US for continued clinical study.  As previously disclosed, the US authority FDA has approved SpectraCure's new and revised study protocol for the clinical study on patients with recurrent prostate cancer. The protocol has also been approved by the UK and Canadian authorities.  The new protocol expands the inclusion criteria for Gleason score, which allows a wider range of candidates to participate in the upcoming phase III study.  In addition, the upper limit on prostate volume has been removed.  This is positive, since the results indicate that the method's efficacy is not restricted by prostate volume. This revision increases the number of prospective patients further.
     
  • Normalized situation in cancer care benefits SpectraCure's clinical trial. The hospitals with whom SpectraCure is cooperating on the clinical study on patients with recurrent prostate cancer have resumed normal operations after the restrictions due to the coronavirus were lifted.
     
  • A rights issue was carried out between June 5 and 23.

Significant events after the second quarter

  • A directed issue was carried out to guarantors and financial advisors in conjunction with the fully subscribed rights issue.
     
  • The last day of trading of paid subscription units (BTU) was August 4, 2020. The paid subscription units were then transformed to shares and Series TO4 subscription warrants. The first day of trading of Series TO4 subscription warrants was August 10, 2020.
 

The attached interim report is in Swedish.

​​​​​​​This information is information that SpectraCure AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on August 25, 2020, at 08:30 a.m.

For more information, please contact:

SpectraCure AB (publ), CEO, Masoud Khayyami, telephone: +46(0) 70 815 21 90

 

SpectraCure was founded in 2003 as a spin off from Lund University and LTH Faculty of Engineering. The company focuses on cancer treatments with medical systems based on laser light sources, connected to the tumour by way of optical fibers, in combination with a photoreactive drug. The method is referred to as Interstitial Photodynamic Therapy, PDT. The treatment is suitable for internal solid tumours of various kind, such as prostate and pancreatic tumours, but also for example for cancers of the head and neck.www.spectracure.com.

The share is traded on Nasdaq First North Premier Growth Market under the ticker SPEC. G&W Fondkommission is the Certified Adviser of the company, e-mail: ca@gwkapital.se, telephone: +46(0) 8-503 000 50.

Documents & Links